The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes—genes that cause cancer when mutated—are responsible for a quarter of all human cancers, including the three tumor ...
Sep 1, 2022
0
34
Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy. Their results, published today in the Journal ...
Aug 3, 2022
0
5
Glioblastoma multiforme (GBM) is one of the most aggressive, fast-growing tumor types, and the most common cancer of the brain with a median overall survival of approximately 15 months. Despite recent advances in treatment ...
Aug 2, 2022
0
5
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor ...
Jun 23, 2022
0
6
In recent years, the immunotherapy field has revolutionized oncology treatment methods by developing therapeutics that help a cancer patient's own immune system fight their disease. However, these treatments have had varied ...
May 16, 2022
0
4
A new Blood Advances study suggests that people with cancer and non-O blood types, such as types A, B, and AB, face an increased risk of developing venous thromboembolism (VTE), or blood clots in the veins, three months ...
Apr 13, 2022
0
9
Every year, roughly 550 women develop ovarian cancer in Finland. Ovarian cancer is difficult to treat and it is commonly fatal, with 320 women dying of ovarian cancer annually in Finland.
Feb 11, 2022
0
12
In a recent study published in Cancer Research, a team led by researchers at Tokyo Medical and Dental University (TMDU) identified a specific small RNA molecule, called a microRNA (miRNA or miR), that has the potential to ...
Oct 5, 2021
0
2
For the first time, scientists from the German Cancer Consortium (DKTK) partner site in Essen/Düsseldorf have discovered stem cells of the hematopoietic system in glioblastomas, the most aggressive form of brain tumor. These ...
Jun 28, 2021
0
6
